AFFX Affymetrix, Inc.

Affymetrix Inc. (Nasdaq:AFFX) today announced the addition of John F. (Rick) Runkel to its management team as Executive Vice President and General Counsel. �Rick has been a successful lawyer for 25 years and brings a wealth of experience to our leadership team,� said Kevin King, president of Affymetrix. �We are very pleased to add Rick and look forward to his contributions in developing and implementing our corporate legal strategy.� Prior to joining Affymetrix, Runkel served as senior vice president and general counsel at Intuitive Surgical Inc, a leader in surgical robotics. Prior to that, he was senior vice president of business development, general counsel and corporate secretary at VISX Inc., a leader in laser vision correction technology. In addition, Runkel spent 17 years practicing law at Sheppard, Mullin, Richter and Hampton LLP, where he was managing partner of the firm�s San Francisco office. �Affymetrix is a company that continues to revolutionize life by powering genetic breakthroughs and enabling individuals to benefit from their own DNA,� said Runkel. �I look forward to being a part of such a quality organization with one of the industry�s strongest IP portfolios.� Runkel received his law and undergraduate degrees from the University of California, Los Angeles. About Affymetrix: Affymetrix GeneChip� microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world�s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,700 systems have been shipped around the world and more than 14,000 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company�s website at www.affymetrix.com. Forward-looking Statements All statements in this press release that are not historical are �forward-looking statements� within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix� �expectations,� �beliefs,� �hopes,� �intentions,� �strategies� or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the management changes discussed in this press release; risks of the company�s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix� Form 10-K for the year ended December 31, 2007, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix� expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo and GeneChip� are registered trademarks owned or used by Affymetrix Inc.